Literature DB >> 33200898

The impact of anterior calyceal stones on the outcomes of percutaneous nephrolithotomy for complex kidney stones: a comparative study.

Ahmet Sahan1, Erdinc Dincer2, Orkunt Ozkaptan2, Alkan Cubuk2, Kasim Ertas3, Bilal Eryildirim2, Oktay Akca2.   

Abstract

BACKGROUND: This study aimed to evaluate the possible effect of anterior calyceal stones on the surgical outcomes of percutaneous nephrolithotomy.
METHODS: Consecutive patients with complex kidney stones from 2012 to 2020 were evaluated retrospectively. In total, 219 patients were divided into 2 groups based on the presence of anterior calyceal stones (group 1; N.=89) or not (group 2; N.=130). The groups were compared in terms of surgical outcomes (i.e., stone-free rate [SFR], operation time, and hemoglobin drop) and complications.
RESULTS: The patient demographics and stone characteristics were similar between the groups. Multiple access was more frequently done in group 1 than it was in group 2 (47.2% vs. 30.8%; P=0.014), and the SFR was lower in group 1 (51.7%) than it was in group 2 (67.7%; P=0.017). Of the anterior calyceal stones in group 1, 42.6% could not be cleaned. However, when excluding patients who have only anterior residual stones from the statistical analysis, the groups had similar SFRs (68.5% vs. 67.7% for group 1 and group 2, respectively).
CONCLUSIONS: The presence of complex kidney stones with anterior calyceal extension are associated with higher residual stones rates in the anterior calyx. Also, it increases multiple access, the operation time, and level of hemoglobin drop.

Entities:  

Mesh:

Year:  2020        PMID: 33200898     DOI: 10.23736/S2724-6051.20.04002-3

Source DB:  PubMed          Journal:  Minerva Urol Nephrol        ISSN: 2724-6051


  1 in total

1.  The High Risk Factors and Preventive Measures of Percutaneous Nephrolithotomy under the Guidance of B-Ultrasound in the Treatment of Postoperative Renal Calculi.

Authors:  Dongshan Pan; Deshi Hong; Fei Wang; Jiebin Lin; Enming Yang; Shixian Wang; Junlong Wang; Xufeng Huang; Kang Li; Lele Yang; ShuiFa Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-21       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.